دورية أكاديمية
Multimorbidity in patients with chronic migraine and medication overuse headache
| العنوان: | Multimorbidity in patients with chronic migraine and medication overuse headache |
|---|---|
| المؤلفون: | D'Amico, Domenico, Sansone, Emanuela, Grazzi, Licia, Giovannetti, Ambra M., Leonardi, Matilde, Schiavolin, Silvia, Raggi, Alberto |
| بيانات النشر: | Wiley-Blackwell Publishing |
| سنة النشر: | 2018 |
| المجموعة: | The University of Queensland: UQ eSpace |
| مصطلحات موضوعية: | comorbidity, disability, medication overuse headache, multimorbidity, quality of life, relapse rate, withdrawal, 2728 Clinical Neurology, 2808 Neurology |
| الوصف: | Objectives: Patients with chronic migraine (CM) display a considerable amount of comorbidities, particularly psychiatric and cardiovascular, and the presence of multiple comorbidities, that is, the so-called multimorbidity, is a risk factor for migraine chronification or maintenance of CM. Our aim was to address the rate and impact of multimorbidity in patients with CM and medication overuse headache (MOH). Materials & Methods: In a sample of patients with CM attending a structured withdrawal for coexisting MOH, we defined multimorbidity as the presence of two or more conditions in addition to CM-MOH. We compared patients with and without multimorbidity for demographic and clinical variables, quality of life, and disability; we also tested whether patients with multimorbidity had higher likelihood to attend emergency room, relapse into CM, and require further withdrawal treatments by 12 months. Results: One hundred and ninety-four patients were enrolled as follows: 61% had at least one comorbidity, the most common being mental (34%), circulatory (18%), and endocrine conditions (13%); 32% were multimorbidity cases. Patients with multimorbidity had higher headaches frequency, older age, lower education and lower employment rates, higher disability and lower QoL. They were more frequently opioids/barbiturates overusers and were more likely to attend ER (OR: 2.36), relapse into CM (OR: 2.19), and undergo another withdrawal (OR: 2.75) by 12 months after discharge, after controlling for age, gender, years of education, and headache frequency. Conclusions: Recognizing multimorbidity in patients with CM-MOH is important to enhance the management of these complex patients, who are at risk of polypharmacy and increased health care utilization. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1600-0404 0001-6314 |
| العلاقة: | orcid:0000-0002-7496-6727; Not set |
| الإتاحة: | https://doi.org/10.1111/ane.13014Test https://espace.library.uq.edu.au/view/UQ:78217a8Test |
| رقم الانضمام: | edsbas.B728464A |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 16000404 00016314 |
|---|